Atara Biotherapeutics, Inc. (ATRA)
After hours: 05:08PM EDT
Chart Events
Performance Outlook
| Previous Close | 15.12 |
| Open | 15.07 |
| Bid | 14.40 x 800 |
| Ask | 15.00 x 900 |
| Day's Range | 14.58 - 15.26 |
| 52 Week Range | 11.81 - 28.20 |
| Volume | 618,459 |
| Avg. Volume | 760,220 |
| Market Cap | 1.236B |
| Beta (5Y Monthly) | 2.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.82 |
| Earnings Date | May 04, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.38 |
- Business Wire
Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
SOUTH SAN FRANCISCO, Calif., October 13, 2021--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced new translational data based on magnetization transfer ratio (MTR) and updated Phase 1 open-label extension (OLE) clinical data in patients with progressive multiple sclerosis (MS) treated with ATA188
- Business Wire
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
SOUTH SAN FRANCISCO, Calif. & CASTRES, France, October 04, 2021--Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America.
- Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., October 01, 2021--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 104,386 restricted stock units of Atara’s common stock to 16 newly hired employees and stock options to purchase an aggregate of 107,813 shares of Atara’s common stock to five such newly hired
